We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

EKF Diagnostics

Manufactures analysers for the measurement of glucose, lactate, hemoglobin, hematocrit and HbA1c for GP surgeries, ph... read more Featured Products: More products

Download Mobile App





EKF and Tosoh Europe N.V. Sign Distribution Agreement for Quo-Test HbA1c POC Analyzer in Middle East and Africa

By LabMedica International staff writers
Posted on 15 May 2020
Print article
Image: EKF’s Quo-Test analyzer (Photo courtesy of EKF Diagnostics)
Image: EKF’s Quo-Test analyzer (Photo courtesy of EKF Diagnostics)
EKF Diagnostics has signed a three-year distribution agreement with (Cardiff, UK) Tosoh Europe N.V. (Tessenderlo, Belgium) for the distribution of its Quo-Test HbA1c point-of-care (POC) analyzer in the Middle East and Africa.

Tosoh Bioscience division is one of the largest global manufacturers of high-performance liquid chromatography (HPLC) equipment for glycated hemoglobin analysis predominantly in core laboratories. Tosoh’s analyzers are frequently used to benchmark and validate POC devices such as Quo-Test. As a desktop analyzer designed for simple and reliable HbA1c measurement for monitoring and managing diabetes in POC settings, such as diabetes clinics and doctors’ surgeries, EKF’s Quo-Test analyzer complements Tosoh’s HPLC technology.

Quo-Test is fully automated and quantifies HbA1c from a 4μL sample taken from a finger prick or venous whole blood. Unaffected by most hemoglobin variants, lab-quality results are available within four minutes and reported in IFCC and DCCT standard units. Also facilitating its use as a POC analyzer, step-by-step instructions are displayed on Quo-Test’s multi-lingual display, minimizing staff training time and minimizing user-related errors.

EKF’s Quo-Test distribution agreement with Tosoh Europe will allow both the companies to work in markets they have previously been unable to access and provide Tosoh Europe with the opportunity to offer new services to suit changing customer requirements. After the initial three-year term for the Middle East and Africa, the distribution agreement has a rolling one-year renewal with the option to extend the agreement into EU countries as required.

“We are delighted to partner with Tosoh Europe as they expand their need for point-of-care HbA1c analysis in a time where those suffering from diabetes are at greater risk,” said Julian Baines, CEO of EKF. “Tosoh is a leading HPLC brand and its analyzers are considered to be the gold standard when validating POC products such as EKF’s Quo-Test. For them to choose our analyzer to complement their lab-based HPLC analyzers for HbA1c testing is a great endorsement of our technology.”




Gold Member
SARS-COV-2 PLUS UK Real Time PCR kit
SARS-COV-2 PLUS UK REALTIME PCR KIT
Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
New
Silver Member
Human Amyloid-Beta Test
Amyloid-beta (1-40) CSF ELISA
New
Auto 5-Part Differential Analyzer
XR-1000 Pure

Print article

Channels

Molecular Diagnostics

view channel
Image: Umbilical cord blood biomarkers may improve preterm infant care (Photo courtesy of Shutterstock)

Umbilical Cord Blood Test Could Identify Preterm Infants at Risk for Medical Complications

Advancements in medical technology and neonatology have significantly improved the care of prematurely born infants. However, these infants still face heightened risks for medical complications, such as... Read more

Immunology

view channel

3D Bioprinted Gastric Cancer Model Uses Patient-Derived Tissue Fragments to Predict Drug Response

Tumor heterogeneity presents a major obstacle in the development and treatment of cancer therapies, as patients' responses to the same drug can differ, and the timing of treatment significantly influences prognosis. Consequently, technologies that predict the effectiveness of anticancer treatments are essential in minimizing... Read more

Microbiology

view channel
Image: The Cytovale System isolates, images, and analyzes cells (Photo courtesy of Cytovale)

Rapid Sepsis Diagnostic Test Demonstrates Improved Patient Care and Cost Savings in Hospital Application

Sepsis is the leading cause of death and the most expensive condition treated in U.S. hospitals. The risk of death from sepsis increases by up to 8% for each hour that treatment is delayed, making early... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.